Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

Rare Tumors

María Florencia Aizpurúa¹  Carolina Valeria Mahuad¹  Marta E. Zerga¹  Gonzalo Garate¹  Maria de los Ángeles Vicente Repáraz¹  Claudia Casali¹ 

[1] Service of Hematology, Department of Internal Medicine, Hospital Alemán, Buenos Aires;

关键词: Lymphoma;    large-cell;    anaplastic;    anaplastic lymphoma kinase;    crizotinib;   

DOI  :  10.4081/rt.2016.6266

来源: DOAJ

【 摘 要 】

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic largecell lymphoma that sustains complete response after 3 years of crizotinib monotherapy.

【 授权许可】

Unknown